Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Parkinson's Disease
Interventions: BIIB094, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 7
States / cities: Chicago, Illinois • Farmington Hills, Michigan • Cleveland, Ohio + 4 more

Conditions: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions: ASP546C; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 28 more

Conditions: Advanced Solid Tumor
Interventions: Part 1 ES002023, Part 2 ES002023; Drug
Lead sponsor: Elpiscience Biopharma, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Los Angeles, California + 4 more

Conditions: Autism Spectrum Disorder, Autistic Disorder, Autism, Asperger's Syndrome, Pervasive Development Disorders
Interventions: Folinic Acid and placebo, Folinic Acid; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 3 Years to 14 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Acetaminophen Toxicity
Interventions: Not listed
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 12 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS
Interventions: APG-115, 5-azacitidine; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 8
States / cities: Gilbert, Arizona • Denver, Colorado • Durham, North Carolina + 5 more

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
Interventions: LY2880070, Gemcitabine; Drug
Lead sponsor: Esperas Pharma Inc.; Other
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Healthy
Interventions: TP 3654; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Older Adults (65 Years and Older)
Interventions: Genius Pillbox; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stroke Ischemic, Sickle Cell Disease
Interventions: Questionnaire/Interview; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 2 Years to 24 Years
Enrollment: 5,247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Multiple Myeloma, Plasma Cell Disorder
Interventions: HDP-101; Drug
Lead sponsor: Heidelberg Pharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Omaha, Nebraska + 2 more

Conditions: Healthy Volunteers
Interventions: ONO-2020, Placebo; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Delirium, Alzheimer Disease
Interventions: Physical Exercise Intervention, Cognitive Training Intervention, Stretching Control, Cognitive Control; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Avon, Indiana • Carmel, Indiana • Fishers, Indiana + 1 more

Conditions: Cancer
Interventions: FACBC PET-CT Imaging; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Obesity
Interventions: GSK2890457, Metformin, Placebo, Liraglutide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 3
States / cities: Chula Vista, California • Miami, Florida • Overland Park, Kansas

Conditions: HIV Infections
Interventions: pGA2/JS7 DNA, Modified vaccinia Ankara/HIV62; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions: KT-474/Placebo, KT-474; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more

Conditions: Angelman Syndrome
Interventions: ION582; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 0 Years to 50 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 6
States / cities: San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: Hepatocellular Carcinoma
Interventions: Carotuximab (TRC105), Sorafenib; Drug
Lead sponsor: Tracon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Birmingham, Alabama • Cleveland, Ohio • Houston, Texas

Conditions: T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma
Interventions: Ibrutinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: New York, New York • Columbus, Ohio

Conditions: Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Interventions: Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush; Drug · Procedure
Lead sponsor: Michael Ohliger, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1614235, Sitagliptin, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miami, Florida • Baton Rouge, Louisiana • Cincinnati, Ohio

Conditions: Healthy Participants
Interventions: AZD3974, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

A Folinic Acid Intervention for Autism Spectrum Disorders

Adduct Dipstick for Diagnosis of Acetaminophen Toxicity

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654

Genius PillBox Study

Evaluating Barriers to Stroke Screening and Prevention in Children With Sickle Cell Disease

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

A Phase 1 Study of ONO-2020 in Healthy Participants

Improving the Recovery and Outcome Every Day After the ICU

Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

Trial of TRC105 and Sorafenib in Patients With HCC

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants